Alcon

Pharmaphorum Media Limited | March 22, 2019

Novartis has finalized plans for the long-awaited spin-off of its Alcon eye care business, announcing that the new company will list on April 9. The Swiss pharma has approval for listing on the SIX Swiss Exchange and the New York Stock Exchange, adding that Alcon is expected to list on Switzerland’s SMI blue-chip stock index on its first trading day. Alcon will have secured debt financing of $3.5 billion, adding that Bank of America Merrill Lynch and UBS were advising Novartis on the trans...

Alcon | April 09, 2019

Alcon is officially a standalone company. The eye care specialist has officially spun out from Swiss pharma giant Novartis. Alcon began trading today on the SIX Swiss Exchange and New York Stock Exchange under the symbol “ALC.” David Endicott, Alcon’s chief executive officer, said that for more than 70 years, Alcon has been dedicated to eye care and health. Now, as a standalone company, Alcon is pursuing additional opportunities to further that mission, he said. “W...

Pharmaphorum Media Limited | October 23, 2018

Novartis’ ophthalmology division Alcon has announced plans to build a digital platform to streamline, simplify and improve cataract surgery for surgeons and patients. Alcon will use its SMART digital technology suite to connect multiple diagnostic and surgical devices through a digital, open cloud-based infrastructure that integrates with clinics’ existing cataract diagnostic equipment, electronic medical record (EMR) systems, and specialist software for cataracts. The aim is ...

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...